What Lipofen-SR Treats: Main Uses and Benefits

This medication is applied across domains where additional symptomatic support is needed for patients experiencing symptoms related to systemic imbalance due to lipid disorders. Lipofen-SR is commonly used to help manage elevated fat-like substances in the blood, specifically for severe hypertriglyceridemia and for mixed dyslipidemia or primary hypercholesterolemia. It is often used during phases when symptoms become more noticeable, providing support that helps ease the overall burden.

Fenofibrate is generally applied in addressing conditions marked by increased physiological stress. This therapy is relevant for easing symptoms that create noticeable physiological strain and may help patients cope more steadily with symptom fluctuations. It provides supportive relief when symptoms interfere with routine activities when conditions involve recurrent or episodic manifestations.

“This support contributes to easing the overall symptom load during periods of heightened symptoms.”

---

Quick Fact: Relief for Physiological Strain

---

Regulatory References

1. NIH MedlinePlus Drug Information

Official Eligibility and Non-Eligibility Status

Regulatory documentation establishes strict criteria for who can and cannot use Lipofen-SR, primarily allowing its use in adult patients with hyperlipidemia or severe hypertriglyceridemia.

Contraindicated Populations (Must Not Use)	Conditional/Restricted Use
Severe Renal Impairment (including dialysis patients)	Mild to Moderate Renal Impairment (requires dose adjustment/monitoring)
Active Liver Disease (including primary biliary cirrhosis)	Geriatric Patients (dose selection must be based on renal function)
Pre-existing Gallbladder Disease	Pregnancy (use only if potential benefit justifies risk)
Nursing Mothers (Lactation)	Hepatic Impairment (use generally not recommended due to lack of data)
Known Hypersensitivity to fenofibrate or any excipients	Patients with pre-disposing factors for myopathy

Age-Related Rules: Safety and efficacy have not been established for pediatric patients (under 18 years of age); therefore, use is not recommended in this age group. Use in older adults is permitted, but the dosage must be carefully determined based on the patient's underlying renal function status.

Comorbidity Exclusions: Absolute prohibition is documented for patients with chronic or acute pancreatitis, except where the pancreatitis is caused by severe hypertriglyceridemia.

The regulatory profile defines precise boundaries for use, making eligibility dependent on the integrity of organ function and the absence of specific pre-existing conditions.

Interactions with other medicines and products

Lipofen-SR (fenofibrate) exhibits several officially documented interactions that primarily relate to pharmacodynamic risk and metabolic pathway influence.

Documented Pharmacodynamic and Pharmacokinetic Interactions

Co-administration with HMG-CoA reductase inhibitors (statins) is documented to increase the risk of Myopathy and Rhabdomyolysis due to an additive pharmacodynamic effect. This heightened risk is also noted in elderly patients, and those with renal impairment, diabetes, or uncontrolled hypothyroidism when taking both medications. Concomitant use with Colchicine similarly increases the risk of muscle toxicity.

Fenofibric acid, the active metabolite, is classified as a mild-to-moderate inhibitor of CYP2C9. This metabolic interaction results in the potentiation of coumarin-type anticoagulants like Warfarin, leading to a formal prolongation of the Prothrombin Time / INR.

Administration Timing and Exposure

Fenofibrate administration must be separated from Bile Acid Sequestrants (resins) by taking it at least 1 hour before or 4–6 hours after the resin, a requirement to prevent impaired absorption. Conversely, the absorption of fenofibrate is enhanced when taken with food.

How Lipofen-SR Works

Lipofen-SR's entire physiological action is driven by a molecular mechanism that directly modulates gene expression in key metabolic tissues. The active metabolite, fenofibric acid, operates by selectively binding to and activating the Peroxisome Proliferator-Activated Receptor alpha (PPARalpha), a specialized nuclear transcription factor. This agonism acts as an instruction set, directing cells to fundamentally change how they synthesize, break down, and transport fats.

---

Modulating Genes to Accelerate Triglyceride Clearance

This mechanism engages genetic cascades to intensely increase the breakdown of fat particles in the bloodstream. Fenofibric acid upregulates the gene for the enzyme Lipoprotein Lipase (LPL), which is crucial for dismantling triglyceride-rich lipoproteins like VLDL. Simultaneously, it downregulates the protein that naturally inhibits LPL, thereby increasing the catabolic function. The resulting physiological effect is the accelerated removal and reduction in the concentration of circulating triglycerides in the plasma.

---

Reprogramming Cholesterol Transport and Composition

The same PPARalpha agonism directs the liver to alter its approach to cholesterol-carrying lipoproteins. It upregulates the genes for Apolipoprotein A-I and ApoA-II, the building blocks of High-Density Lipoprotein (HDL). This action enhances the efficiency of Reverse Cholesterol Transport. Furthermore, the mechanism induces a shift in Low-Density Lipoprotein (LDL), favoring a transition from smaller, denser particles to a larger, more buoyant composition.

Administration Instructions

Lipofen-SR (fenofibrate) is a capsule taken by oral route, and the administration should follow the prescribed dosing instructions.

Dosage and Timing

Lipofen-SR must be taken once daily with food to optimize the absorption of the medicine. The capsule should be swallowed whole; it must not be crushed, dissolved, or chewed.

• Adult Dosing: The typical dose for primary hypercholesterolemia or mixed dyslipidemia is 150 mg once daily. For severe hypertriglyceridemia, the initial dose is 50 mg to 150 mg per day, with the maximum daily dose being 150 mg.
• Dose Adjustment: Dosage should be individualized based on the patient's response. The healthcare provider will assess lipid levels 4 to 8 weeks after starting treatment to determine if a dose adjustment is necessary.

Special Procedural Rules

• Co-administration with Bile Acid Resins: If the patient is also taking a bile acid binding resin (such as cholestyramine), Lipofen-SR must be administered at least 1 hour before or 4 to 6 hours after the resin to prevent the resin from impeding its absorption.
• Missed Dose: If a dose is missed, the patient should skip the missed dose and take the next dose at the regular scheduled time. Do not take two doses at the same time to make up for the forgotten dose.

Research Evidence / Overview of Studies for Lipofen-SR

The research evidence for fenofibrate (Lipofen-SR) consists of studies that explored patterns of change in blood fat levels and associated health patterns in different groups of patients. The research primarily focuses on formal methods like Randomized Controlled Trials (RCTs) and large-scale observational studies to monitor patterns of change over defined time intervals. This overview summarizes the structure of the available evidence without offering clinical guidance or interpretation of personal outcomes.

---

Evidence for Use in Managing Severely Elevated Triglycerides

Researchers utilized short-term randomized trials to study adults diagnosed with severe hypertriglyceridemia (very high levels of fat in the blood). These studies were primarily interested in monitoring how the medicine was evaluated based on key biomarkers, especially Triglyceride levels in adults with severe hypertriglyceridemia. Short-term RCTs reported on the measured shifts in Triglyceride levels across the studied adult populations.

What remains uncertain is the research evidence for the association between the measured lipid changes and the incidence of the severe acute complication, acute pancreatitis. There is a lack of large, long-term randomized trials specifically designed to track and determine a definitive pattern for the incidence of this complication as a primary research goal.

---

Evidence for Use in Mixed Dyslipidemia and Cholesterol Management

Clinical evaluation includes evidence from large-scale, long-term Cardiovascular Outcome Trials (CVOTs). The studies primarily focused on two areas: measuring changes in the key blood fat markers, and tracking the occurrence of Major Adverse Cardiovascular Events (MACE). The research describes recorded data on key lipid biomarkers, particularly in Triglycerides and HDL-C levels. Regarding the broader cardiovascular outcomes, the overall findings from these major long-term studies, where fenofibrate was often evaluated alongside standard care (including statins), reported neutral findings concerning cardiovascular event reduction in the general high-risk populations studied. Evidence to isolate the effects of fenofibrate separate from statin therapy remains limited due to the wide use of statin therapy in the control groups.

---

What Remains Uncertain About the Research Landscape

Key limitations include the fact that results apply only to the specific populations studied, and that follow-up durations were limited to about five years in the major trials. Research is ongoing to clarify the precise role of this medicine when studied in combination with modern standard-of-care treatments, particularly statins. Additionally, the lack of dedicated, powered trials means certainty remains low for outcomes such as the definitive reduction of acute pancreatitis risk.

Key Studies & References DailyMed: FENOFIBRATE tablet (Includes information on severe hypertriglyceridemia indication and limitations)

Common questions about Lipofen-SR (FAQ)

---

Q: Is Lipofen-SR the same as other fenofibrate medications?

Lipofen-SR contains the same active ingredient, fenofibrate, as other medications in its class. However, the official product information indicates that fenofibrate products can differ in their inactive ingredients and the specific formulation’s release mechanism. Lipofen-SR is specifically formulated as a sustained-release (SR) capsule, which influences how the medicine is absorbed over time.

---

Q: How quickly should I expect Lipofen-SR to start lowering my cholesterol?

Regulatory information indicates that your healthcare provider will typically assess your lipid (fat) levels four to eight weeks after starting treatment or after any dose change. This timeframe is used to determine the patient's response to the medicine.

---

Q: Can Lipofen-SR cause stomach or digestion problems?

Yes, regulatory documents list gastrointestinal disturbances among the common adverse reactions reported in clinical trials for this medicine. These can include symptoms such as abdominal pain, nausea, and flatulence.

---

Q: Do I need to change my diet while I'm taking Lipofen-SR?

Official prescribing information indicates that Lipofen-SR is used as an adjunct (in addition) to a proper lipid-lowering diet. Patients are typically placed on an appropriate diet before starting the medicine and are advised to continue following that diet throughout the course of treatment.

---

Q: Do other medications like blood pressure pills interact with Lipofen-SR?

Official labeling warns of interactions with certain drugs, including statins, Warfarin, and bile acid binding resins. Potential interactions with any specific medication, including blood pressure treatments, require evaluation based on individual patient circumstances.

---

Q: Why do some Lipofen-SR pills look different than others?

The appearance of the medicine, including its color, shape, and imprints, is determined by the manufacturer of that specific dosage form. Regulatory documents, such as DailyMed, show that different strengths, or generic versions of the active ingredient fenofibrate, may have different appearances.

---

Q: Can taking Lipofen-SR make my skin more sensitive to the sun?

Postmarketing experience reported in regulatory documents has noted cases of photosensitivity reaction with fenofibrate products. This is an increased sensitivity of the skin to sunlight. Discussing sun exposure with a healthcare provider may be appropriate for patients.

---

Q: Is Lipofen-SR a long-term or a short-term medication?

Lipofen-SR is generally used for the long-term, chronic management of high lipid levels. Regulatory guidelines state that if a patient does not achieve an adequate response after two months of treatment at the maximum recommended dose, therapy should be withdrawn.

---

Q: Is it normal to feel a bit nauseous when first starting Lipofen-SR?

Nausea is reported as a common adverse reaction in clinical trial data for this type of medication. Regulatory information does not specifically address if this symptom is more likely to occur only at the start of therapy, but it is a known possible effect.

---

Q: Can a person with mild kidney issues use Lipofen-SR?

The official product information states that Lipofen-SR is contraindicated (must not be used) in patients with severe kidney impairment. For those with mild to moderate kidney impairment, regulatory guidelines state that the dosage should be carefully adjusted, and renal function monitoring is necessary.

---

Q: Why is Lipofen-SR sometimes prescribed along with a statin?

Fenofibrate, the active component, has been studied in combination with statins in clinical trials to evaluate the effects on lipid markers and cardiovascular outcomes. Official information notes that this combination is sometimes used, but it also increases the reported risk of muscle problems.

---

Q: How long does Lipofen-SR stay in your system after you stop taking it?

Regulatory documents on pharmacokinetics report that the active compound, fenofibric acid, has an average elimination half-life of approximately 20 hours. This means it generally takes a few days for the medicine to be fully cleared from the body.

---

Q: Can Lipofen-SR help improve good cholesterol (HDL)?

Yes, official regulatory labeling indicates that Lipofen-SR is used as an adjunct to diet to increase High-Density Lipoprotein Cholesterol (HDL-C), which is commonly referred to as 'good cholesterol.'

---

Q: Are there generic versions of Lipofen-SR available?

The active ingredient, fenofibrate, is available in generic capsule formulations that have been approved by the FDA.

---

Q: Is it possible to be allergic to an ingredient in Lipofen-SR?

Official regulatory documentation states that the medicine is contraindicated (not to be used) in anyone with a known hypersensitivity, or allergic reaction, to fenofibrate or to any of the inactive ingredients (excipients) in the product.

---

Q: What is the typical timeframe for seeing the maximum effect of Lipofen-SR?

Pharmacokinetic data shows that fenofibric acid, the active form of the drug, reaches a steady concentration in the bloodstream within about five days. Efficacy is formally evaluated by a healthcare provider to assess treatment response after four to eight weeks.

---

Q: Are headaches a common side effect reported by Lipofen-SR users?

Yes, clinical trial data lists headache as a common adverse reaction reported with fenofibrate products.

---

Q: Does Lipofen-SR help prevent heart attacks or strokes?

Regulatory documents explicitly state that Lipofen-SR is not indicated for the prevention of heart attacks or strokes. Clinical studies have reported neutral or mixed findings regarding its ability to reduce major adverse cardiovascular events (MACE) in the general high-risk populations studied.

---

Q: Does Lipofen-SR cause drowsiness or dizziness?

Official adverse reaction reports do not explicitly list drowsiness or dizziness as common or uncommon side effects. The most frequently reported adverse reactions generally relate to gastrointestinal issues and changes in liver enzyme levels.

---

Q: Why is Lipofen-SR considered a fibrate drug?

Lipofen-SR is classified as a fibrate (fibric acid derivative) because its active component, fenofibric acid, works by activating a specific nuclear receptor in the body called PPARalpha (Peroxisome Proliferator-Activated Receptor alpha). This is the mechanism that defines its pharmacological class.

---

Q: Do people typically stop taking Lipofen-SR once their levels improve?

Lipofen-SR is indicated for chronic conditions. Regulatory documentation states that therapy should be withdrawn if an adequate lipid response is not demonstrated within two months of treatment at the maximum recommended dose.

---

Q: Does Lipofen-SR affect blood sugar levels in people with diabetes?

Official labeling notes that elevations in fasting serum glucose and hemoglobin A1c (HbA1c), a marker of long-term blood sugar control, have been reported with fenofibrate treatment. Monitoring of these levels may be a necessary part of management for patients with diabetes.

---

Q: What kind of improvement should I look for in my blood work results from Lipofen-SR?

Official product information describes the intended improvements to blood fat levels. These generally include a reduction in triglycerides, a reduction in LDL-C (Low-Density Lipoprotein Cholesterol), and an increase in HDL-C (High-Density Lipoprotein Cholesterol).

How to Store and Dispose of LIPOFEN (Fenofibrate) Capsules

LIPOFEN capsules must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The medication must be protected from moisture and stored in a tight, light-resistant container.

---

Handling and Disposal

The product must be kept out of the reach of children to ensure safety. For product integrity, storage must avoid environments that permit temperature excursions beyond the specified 15 C to 30 C range.

To dispose of unused or expired LIPOFEN, discard the product according to local regulations.